Loading...
•
Mar 31, 2023
C4 Therapeutics Q1 2023 Earnings Report
C4 Therapeutics reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights.
Key Takeaways
C4 Therapeutics reported a net loss of $34.8 million for the first quarter of 2023, with revenue of $3.8 million. The company's cash, cash equivalents, and marketable securities totaled $305.0 million as of March 31, 2023, expected to provide runway into 2025.
Progressed three orally bioavailable degrader programs through the clinic and presented new preclinical data from CFT1946 at AACR.
CFT7455 Phase 1/2 clinical trial continues in MM and NHL.
CFT8634 Phase 1/2 clinical trial continues in synovial sarcoma and SMARCB1-null solid tumors.
CFT1946 Phase 1/2 clinical trial was initiated in January and is enrolling patients with BRAF V600 solid tumors.
Revenue by Segment
Forward Guidance
C4T expects that its cash, cash equivalents and marketable securities as of March 31, 2023, along with cost savings, will be sufficient to fund planned operating expenses and capital expenditures into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...